Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Genentech-Lilly deals clear some of the air

The settlement of the human growth hormone patent suit between Genentech Inc. and Eli Lilly and Co. is likely to have repercussions beyond the $145 million GNE will receive from the agreement.

Under the settlement announced last week, Lilly agreed to pay GNE $145 million plus additional payments contingent on the sale of certain products. Lilly will make an initial payment of $25 million. That payment won't increase

Read the full 691 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE